#United States #New York #Class Action #Gross Law Firm #Regeneron Pharmaceuticals

Legal Notice for Regeneron Pharmaceuticals Shareholders

In a significant announcement for investors, The Gross Law Firm has issued a crucial notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Any shareholders who bought shares of Regeneron within a specified time frame are being urged to reach out to the law firm to participate in a pending class action lawsuit.

Important Details

The class period for the lawsuit spans from November 2, 2023, to October 30, 2024. During this time, the complaint alleges that Regeneron misrepresented critical financial information related to its product Eylea. Shareholders who may have suffered losses due to these misleading claims are encouraged to get in touch with The Gross Law Firm as soon as possible.

Allegations Against Regeneron

The allegations against Regeneron are serious and multifaceted. The lawsuit claims that the company:
1. Misleading Statements: Issued materially false and misleading statements regarding its financial operations related to credit card payment practices.
2. Undisclosed Financial Arrangements: Failed to disclose that it was paying credit card fees to distributors under the condition that they would not charge Eylea customers more when paying by credit card.
3. Price Concessions and Competitive Edge: These undisclosed payments were claimed to have effectively reduced the price that customers paid for Eylea through credit card transactions, thereby providing Regeneron with an unfair competitive advantage in the market.
4. Inflated Sales Figures: Allegedly misled investors by reporting inflated sales figures, as payments to distributors were not reported as price concessions, impacting average sales prices reported to federal agencies and violating aspects of the False Claims Act.

The highly sensitive nature of pricing in the retinal treatment market, as well as the fact that retina practices pay close attention to pricing dynamics, makes these claims particularly significant.

Next Steps for Investors

Investors who bought shares of Regeneron during the defined class period have a limited window to register for the lawsuit. The deadline for becoming a lead plaintiff is set for March 10, 2025. Interested shareholders should not delay in registering and can do so through the links provided. By registering, they will be integrated into a portfolio monitoring service that will provide updates on the case's progress and issues.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized as a leading class action law firm aiming to protect the rights of investors who have suffered due to corporate fraud and misleading business practices. Their mission is to ensure companies adhere to ethical business standards and avoid participating in illegal activities that could harm investors. Those affected are encouraged to reach out to the firm to discover their rights and possible recovery options.

For inquiries, shareholders can contact The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

By taking prompt action, shareholders of Regeneron Pharmaceuticals can be part of a movement towards accountability and, potentially, recovery of their lost investments. Do not miss out on this opportunity!